Cart: 0 items $0.00 2
Buy-Meds24.com
Currency:
|    Language:
Only FDA approved drugs Save and easy buy! Satisfaction guaranted World lowest price
Currency:
|    Language:
Hepcinat-LP
SEARCH BY NAME: A B C D E F G H I J K L M N O P R S T U V W X Y Z
Hepcinat-LP

Hepcinat-LP is an antiviral medication used to treat hepatitis C (Hep C). Hepcinat-LP is a combination of ledipasvir and sofosbuvir. It is approved for people with genotype 1 hepatitis C virus.

Select Doses: 90/400 mg
90/400 mg
28pills
Hepcinat-LP
$2 399.90
$1 999.99
$71.43 per pills
+ Free standard airmail service
+ Package delivery insurance
+ Next orders 10% discount
ADD TO CART
save: $0.00
+ Free standard airmail service
+ Package delivery insurance
+ Next orders 10% discount
90/400 mg
56pills
Hepcinat-LP
$3 999.50
$3 332.99
$59.52 per pills
+ Free standard airmail service
+ Package delivery insurance
+ Next orders 10% discount
ADD TO CART
save: $666.96
+ Free standard airmail service
+ Package delivery insurance
+ Next orders 10% discount
Package Example
Your order will be packed safe and secure and dispatched within 24 hours. This is exactly how your parcel will look like (pictures of a real shipping item). It has a size and a look of a regular private letter (9.4x4.3x0.3 inches or 24x11x0.7cm) and it does not disclose its contents

November

22
Delivery period
14-21 days
10$ Tracking# available in 4 days
Delivery period
5-9 days
30$ Tracking# available in 2 days
Testimonials Product Description
There is no review for this product at the moment, but you can be the first to add or you can read more in Testimonials Page about related products.
Add Review

Hepcinat-LP



Hepcinat-LP is an official generic (Ledipasvir 90 mg + Sofosbuvir 400 Mg) from Indian producer Natco Pharma for Hepatitis C infected with 1 genotype. The drug does not require a combination with interferon or Ribavirin.


Ledipasvir and Sofosbuvir, which are part of the tablets, when ingested, paralyze the enzymes necessary for the development and reproduction of the hepatitis C virus.



The main advantages of Hepcinat-LP:

  • High efficiency (97-100%);
  • Absence of side effects;
  • Complete preservation of the routine of life;
  • Does not affect the blood formula (as preparations containing interferon);
  • Availability and price;
  • No chance of a virus return.

Antiviral therapy against hepatitis C on this drug is easily tolerated and has an incredibly simple scheme - you just drink one tablet a day and after 3 months there is no hepatitis (PCR negative), does not require constant monitoring by a doctor.


Do not take the pill along with another medication that contains Sofosbuvir - there may be an overdose and an increase in side effects. Categorically prohibited sharing with tenofovir, elvitegravir and emtricitabine. It is not recommended to take Hepcinat-LP together with tipranavir, St. John's wort, rosuvastatin or phenytoin. These drugs interfere with the assimilation of Hepcinat-LP and may affect the effectiveness of treatment.


The Hepcinat-LP tablet is taken once a day. It is better to take the medicine while eating, with a small amount of water.


Before taking medication, read the instructions carefully.


The recommended dose of Hepcinat-LP is one tablet of 400 mg of Sofosbuvir and 90 mg of Ledipasvir (in one tablet) orally once a day with or without food.


Patients with 1 genotype of the hepatitis C virus are recommended to be treated for 12 weeks. Patients with compensated cirrhosis should take Hepcinat-LP 24 weeks.


The medicine can not be taken if the active substance or any of the components is intolerant and to persons under 18 years of age. Hepcinat-LP is not given to pregnant women and women during lactation.


After 12 weeks of therapy, blood should be given to determine the virus. If a sustained virologic response is not observed after 12 weeks of treatment, therapy should be discontinued. This means that in your particular case the medicine was ineffective and it is necessary to select another drug.


Before starting therapy, always consult your doctor.


Keep the drug in a dry place, protected from sun and inaccessible to children, at a temperature of 15 to 30 ° C. Date of manufacture and shelf life are indicated on the packaging.




Common use


The active ingredient present in Hepcinat-LP is a two drug combination for the treatment of hepatitis C. It is administered as a single daily pill containing 90 mg of the viral NS5A inhibitor ledipasvir and 400 mg of sofosbuvir, a nucleotide inhibitor of the viral RNA polymerase.


Sofosbuvir is a nucleotide analog used in combination with other drugs for the treatment of hepatitis C virus (HCV) infection. Sofosbuvir inhibits the RNA polymerase that the hepatitis C virus uses to replicate its RNA.


Ledipasvir (formerly GS-5885) is a drug for the treatment of hepatitis C. Ledipasvir is an inhibitor of the hepatitis C virus NS5A protein.


The ledipasvir / sofosbuvir combination is a direct-acting antiviral agent that interferes with HCV replication and can be used to treat patients with genotypes 1a or 1b without PEG-interferon or ribavirin.



Dosage and direction


Usual Adult Dose for Chronic Hepatitis C: 1 tablet orally once a day


Duration of Therapy:

  • Therapy-naive patients without cirrhosis: 12 weeks; 8 weeks can be considered if pretreatment HCV RNA less than 6 million international units/mL
  • Therapy-naive patients with cirrhosis: 12 weeks
  • Therapy-experienced patients without cirrhosis: 12 weeks
  • Therapy-experienced patients with cirrhosis: 24 weeks


Comments:

  • Relapse rates are affected by baseline host and viral factors and differ between durations of therapy for some subgroups.
  • Therapy-experienced patients are those patients who have failed treatment with either peginterferon alfa/ribavirin or peginterferon alfa/ribavirin/HCV protease inhibitor.


Use: For the treatment of chronic hepatitis C genotype 1 infection



Precautions


You should not use Hepcinat-LP if you are allergic to ledipasvir or sofosbuvir, or if you are also taking sofosbuvir tablets.


To make sure Hepcinat-LP is safe for you, tell your doctor if you have:

  • liver problems other than hepatitis C; -kidney disease (or if you are on dialysis);
  • HIV or AIDS; or a heart rhythm problem for which you take a medicine called amiodarone (Cordarone, Pacerone).


You should not use Hepcinat-LP with ribavirin if you have:

  • severe kidney disease;
  • a hemoglobin blood cell disorder such as sickle-cell anemia or thalassemia; or if you are pregnant, or if you are a man and your sexual partner is pregnant.


Hepcinat-LP is not expected to harm an unborn baby. But Hepcinat-LP is sometimes used together with ribavirin which can cause birth defects or death in an unborn baby. You may need to have a negative pregnancy test before taking ribavirin and every month during your treatment.


Avoid taking an antacid within 4 hours before or 4 hours after you take Hepcinat-LP. This especially includes antacids that contain aluminum or magnesium.


Taking Hepcinat-LP will not prevent you from passing hepatitis C to other people.


Hepcinat-LP is not approved for use by anyone younger than 18 years old.



Contraindications


Drinking alcohol while taking Hepcinat-LP can cause dangerous or unwanted side effects.


If you are a woman, do not take ribavirin if you are pregnant. If you are a man, do not take ribavirin if your sexual partner is pregnant. An unborn baby could also be harmed if a man fathers the child while he is taking ribavirin. Tell your doctor right away if a pregnancy occurs while either the mother or the father is taking ribavirin.


It is not known whether ledipasvir and sofosbuvir passes into breast milk or if it could harm a nursing baby. Tell your doctor if you are breast-feeding a baby.



Possible side effects


Common Hepcinat-LP side effects may include: weakness; headache; or tired feeling.


If you also take a heart medication called amiodarone, call your doctor at once if you have:

  • extreme tiredness;
  • unusual weakness or lack of energy;
  • confusion or memory problems;
  • a light-headed feeling, like you might pass out;
  • slowed breathing; or chest pain, slow heartbeats, weak pulse.


This is not a complete list of side effects and others may occur. You may report side effects to FDA at 1-800-FDA-1088.



Drug interaction


Tell your doctor about all medicines you use, and those you start or stop using during your treatment with Hepcinat-LP, especially:

  • amiodarone;
  • ribavirin;
  • Atripla;
  • digoxin;
  • other drugs to treat hepatitis C, such as simeprevir or sofosbuvir;
  • ritonavir when used with tipranavir; rosuvastatin;
  • St. John's wort;
  • Stribild;
  • tenofovir when used in combination with atazanavir, darunavir, lopinavir, or ritonavir;
  • seizure medicine - carbamazepine, oxcarbazepine, phenobarbital, phenytoin; stomach acid reducers - cimetidine, esomeprazole, famotidine lansoprazole, nizatidine, omeprazole, pantoprazole, ranitidine, and others;
  • or tuberculosis medicine - rifabutin, rifampin, rifapentine.


This list is not complete. Other drugs may interact with ledipasvir and sofosbuvir, including prescription and over-the-counter medicines, vitamins, and herbal products.



Missed dose


If you miss taking a dose of Hepcinat-LP and it is within 18 hours of when you were supposed to take it, take it as soon as possible. If it is after 18 hours from when you were supposed to take it, wait and take the next tablet at your regular time. Do not take a double dose. If you find that you are not able to take your medication as prescribed and directed, talk to your nurse or doctor right away.



Overdose


If you think you have used too much of Hepcinat-LP - seek emergency medical attention or call the Poison Help line at 1-800-222-1222.



Storage


Store this medicine at 25°C (77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F), away from moisture and heat. Keep all drugs out of the reach children and pets.

 

 

Disclaimer


We provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information at the site cannot be used for self-treatment and self-diagnosis. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.